The stock of Immunocore Holdings plc ADR (IMCR) has seen a -5.48% decrease in the past week, with a -26.23% drop in the past month, and a -44.91% decrease in the past quarter. The volatility ratio for the week is 3.12%, and the volatility levels for the past 30 days are at 4.60% for IMCR. The simple moving average for the last 20 days is -16.80% for IMCR’s stock, with a simple moving average of -40.45% for the last 200 days.
Is It Worth Investing in Immunocore Holdings plc ADR (NASDAQ: IMCR) Right Now?
Additionally, the 36-month beta value for IMCR is 0.75. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IMCR is 48.45M and currently, short sellers hold a 13.78% ratio of that float. The average trading volume of IMCR on June 27, 2024 was 765.70K shares.
IMCR) stock’s latest price update
The stock price of Immunocore Holdings plc ADR (NASDAQ: IMCR) has dropped by -4.15 compared to previous close of 35.44. Despite this, the company has seen a fall of -5.48% in its stock price over the last five trading days. globenewswire.com reported 2024-06-01 that Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Analysts’ Opinion of IMCR
Many brokerage firms have already submitted their reports for IMCR stocks, with Leerink Partners repeating the rating for IMCR by listing it as a “Outperform.” The predicted price for IMCR in the upcoming period, according to Leerink Partners is $74 based on the research report published on April 29, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see IMCR reach a price target of $60. The rating they have provided for IMCR stocks is “Overweight” according to the report published on November 20th, 2023.
IMCR Trading at -32.13% from the 50-Day Moving Average
After a stumble in the market that brought IMCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.87% of loss for the given period.
Volatility was left at 4.60%, however, over the last 30 days, the volatility rate increased by 3.12%, as shares sank -26.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.84% lower at present.
During the last 5 trading sessions, IMCR fell by -5.48%, which changed the moving average for the period of 200-days by -39.19% in comparison to the 20-day moving average, which settled at $40.22. In addition, Immunocore Holdings plc ADR saw -50.28% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMCR starting from St Leger Tina Amber, who sale 4,375 shares at the price of $64.06 back on Apr 01 ’24. After this action, St Leger Tina Amber now owns 0 shares of Immunocore Holdings plc ADR, valued at $280,262 using the latest closing price.
Berman David M, the HEAD OF R&D of Immunocore Holdings plc ADR, sale 36,509 shares at $68.59 during a trade that took place back on Feb 28 ’24, which means that Berman David M is holding 0 shares at $2,504,158 based on the most recent closing price.
Stock Fundamentals for IMCR
Current profitability levels for the company are sitting at:
- -0.25 for the present operating margin
- 1.0 for the gross margin
The net margin for Immunocore Holdings plc ADR stands at -0.23. The total capital return value is set at -0.08. Equity return is now at value -17.05, with -7.80 for asset returns.
Based on Immunocore Holdings plc ADR (IMCR), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at -0.02. The debt to equity ratio resting at 1.31. The interest coverage ratio of the stock is -10.15.
Currently, EBITDA for the company is -38.47 million with net debt to EBITDA at 10.21. When we switch over and look at the enterprise to sales, we see a ratio of 3.58. The receivables turnover for the company is 4.77for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.96.
Conclusion
In conclusion, Immunocore Holdings plc ADR (IMCR) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
